Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials
This article was originally published in The Pink Sheet Daily
Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.
You may also be interested in...
Deal Watch: Oncology A Recurring Theme In Recent Spate Of Transactions
TetraLogic uses cash from its recent IPO to bring form to its oncology pipeline via the acquisition of Shape Pharmaceuticals. Also, GlaxoSmithKline becomes the latest big pharma to partner with MD Anderson Cancer Center’s Moon Shots program and Mersana will collaborate with Takeda on antibody-drug conjugates for cancer.
Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance
Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.
Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.